The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced significant regulatory updates in July 2025, focusing on Recognition and Reliance, competition law compliance, and new equivalence requirements for medical devices. These changes aim to streamline market access while ensuring safety, innovation, and fair competition in the healthcare sector.
This blog provides an in-depth analysis of the latest updates, their implications for manufacturers, suppliers, and healthcare stakeholders, and actionable steps for compliance.
Competition Law Compliance: Upholding Ethical Business Practices
The MHRA and the Association of British Healthcare Industries (ABHI) have reinforced strict competition law guidelines to prevent anti-competitive behavior. This include:
Why It Important:
ABHI Code Ethical HealthTech StandardsAction Step: Companies must conduct internal training in order to avoid inadvertent breaches.
Equivalence Requirements for Medical Devices
A major update under Annex C introduces stricter “Entire Equivalence” criteria for medical devices. Manufacturers must demonstrate similarity in:
A. Technical Characteristics
B. Biological Characteristics
C. Clinical Characteristics
Key Considerations:
Implications:
| Aspect | EU Equivalence | UK "Entire Equivalence" |
|---|---|---|
| Meet all three characteristics | Not always required (justified differences allowed) | Mandatory (all must be fully met) |
| Access to technical documentation | Published data sometimes accepted | Strict access required (minimal reliance on literature) |
| Clinical tolerance for differences | Some allowed if justified | Little to no tolerance |
| Regulatory effect | Easier to leverage existing data | New clinical studies may be needed |
Action Step: Review device portfolios and align with UK standards.
Recognition & Reliance: New Market Access Routes
The MHRA has introduced four regulatory routes for medical devices, depending on risk classification and origin of approval.
Route 1: Low-Risk Devices (Self-Declaration)
Eligible Devices:
Accepted Approvals: USA, Canada, Australia, EU.
Key Features:
Route 2: EU MDR/IVDR CE-Marked Devices (On Hold)
Eligible Devices:
Status: Not yet implemented (subject to future consultation).
Route 3: Moderate/High-Risk Devices (Reliance Pathway)
Eligible Devices:
Accepted Approvals: USA, Canada, Australia.
Key Features:
Route 4: Higher-Risk & Active Devices (Strict Scrutiny)
Eligible Devices:
Accepted Approvals: USA (510(k), PMA), Canada, Australia.
Key Features:
Exclusions/Inclusions:
UKCA Marking Strategy: Key Considerations
Manufacturers must decide between:
Advantages of UKCA Strategy:
Physical UKCA Mark Requirements:
Mandatory unless:
Quality Management System (QMS) Updates
New QMS requirements include:
Supplier Requirements:
Next Steps for Industry Stakeholders
Key Deadlines:
Conclusion
The MHRA’s July 2025 updates introduce stricter equivalence rules, new reliance pathways, and enhanced competition law enforcement. Manufacturers must:
By staying proactive, businesses can navigate these changes effectively while maintaining market access and compliance.
Need Further Guidance?
Contact Sushvin For Best Quality and Regulatory Services For Medical Devices & Pharmaceutical
Industries in UK
Sushvin offers a comprehensive range of services tailored to meet the diverse needs of our clients. Whether you're seeking regulatory support, technical documentation, or strategic consulting, we're here to help you succeed.
Stay informed with the latest insights, updates, and expert tips - subscribe to our monthly newsletter today!
Medical Device Regulatory Updates - Monthly Newsletter | SUSHVIN Consultancy
